• Save
2ข้อเสนอควบคุมค่ายาcsmbs131109
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

2ข้อเสนอควบคุมค่ายาcsmbs131109

on

  • 687 views

 

Statistics

Views

Total Views
687
Views on SlideShare
685
Embed Views
2

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 2

http://www.oha-th.com 2

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

2ข้อเสนอควบคุมค่ายาcsmbs131109 Document Transcript

  • 1. F F FF F F .. F 13 2552 F F F F F / F F F F F F F F F F F F F F F F F F F F F F (Diagnosis RelatedGroup: DRG) F F F F F F F F F F F F F (Fee-for-service) F F F F F F F F F F F F 1 F F F . . 2545- 2552 : F 2552 31
  • 2. 2 F F F F F FF F . . 2547 F F F FF F F DRG F F F F FF F F F F F F F F F F F F FF DRG 2 F F F F 2532 - 2552 : F 2552 F F1 2551 31 2552 F F F F F F F (F 83) F F 900 F F 34 F F F F F F F F 35 F F F FF F F F 60(~20,000 F ) F F F F F F F F F F F F F F F F F F F F F F F F FF F F F FF F F F F F F F FF F F
  • 3. 3 1) F F F F F F F FF F F F ( F . .2550 F F F F F F F F F ) F F F F F F 2) F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F FF F 3) F F F F F F F FF F F F F F F (Original Brand) F F F F F F F F F F F F F F F F F 4) F F(1) . . 2523 F F F FF F F F F F F F F F FF (2) F F F F F F F F F (3) F F F F F F F 1) F F F F F F
  • 4. 4 2) FF ( .) ( .) ( .) F F F F F . . 2553 - 2555 F F F F F F F F FF F (1) F F F F F F F 34 F (2) F F F (3) FF 34 F F FF F F F F FF F (4) F FF F F F F F F F F FF (acaedemic detailling) F F F F F F F F F (5) F F FF F F F F F F F F F F ( F DRG) F (Differential capitation) F F (point system) F F F F F F F F F F F F F F F FF F FF 3) 3 2552 F F F F 34 F F F F F 30 F F F F F F F FF F 12 2552 . F F F F F 3.1) F 2542 F F F FF F F F F F F F F F F F FF F F F F F F F
  • 5. 5 3.2) F F FF F (1) F Foriginal manufacturer F generic equivalent F F (2) F F F F F F F F F therapeutic equivalent F F F F 10 . .2552 F 6 2552 F F F 31 F 34 F 1 1 F F F 31 F . F . . . ( F) (N=7) (N=16) (N=8) (N=31) ( ) 6,914,378 5,675,890 4,058,066 16,648,334 - ( ) 3,107,884 1,727,876 1,781,563 6,617,323 (%) 45% 30% 44% 40% F ( ) 8,524,258,820 3,323,777,098 3,399,923,178 15,247,959,096 F ( ) 5,580,080,654 2,105,324,655 2,355,071,378 10,040,476,687 F (%) 65% 63% 69% 66% 31 F 16.6 F F F 40 . F . F15,247.95 F F F F 66 F F F F F F F FF F F F F F F F F F F F F F F F F F F 2
  • 6. 6 2 F F F . 27 F F F F F F F F F (F (x1,000 F F (x1,000 ) ) ) (F ) F 16,648 15,248 6,617 10,0401. FAnti-ulcerant /variceal bleeding 646 715 261 666 599 3.9%2. F F F FNSAIDs/ anti-osteoarthritis 891 1,022 671 993 415 2.7%3. FAntilipidemia 855 1,467 377 1,266 1,009 6.6%4. F F F Angiotensin convertingenzyme (ACE) inhibitors 263 125 74 99 87 0.6%5. FAngiotensin-II receptor blockers(ARBs) 327 622 280 558 158 1.0%6. F Antiplatelets 475 468 24 37 376 2.5%7. F F Glucosamine 442 442 2.9%8. Drugaffecting bone metabolism 190 738 187 712 712 4.7%9. F Anticancers 129 1,441 21 647 647 4.2% 1- 9 4,614 7,679 2,057 5,488 4,851 31.8% F F 3, 7, 8 6 F F F (Plavix) F (Colpidogrel) F 5 4) F . F F F 2 2552 F F F F F F F F F F F FF 2 F
  • 7. 7 (1) F F F (Negative druglists) F F F F F F Glucosamine F F F F (Osteoarthritis) F F F F F 31 F F 442 F F 2.9 F FF 31 F (2) F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F F 31 F F 1,467 F F 1,265 F F F1,009 F F 6.6 F FF 31 F (3) F F F (Bonemetabolism) F F F F F F F F F F F F F F F F F F F F F (Bonemetabolism) F F F F 1 F F F F F F F F F F F F F F F F F F F F 31 F F 738 F F 712 F F F F F F F F F 712 F F 4.7 F 31 F1 F F F F . F
  • 8. 8 F F F F FF FF F F F 2,162 F F 14 F F 31 FF F F F F FF F F F F F F F 1. F F F FF F 2553 F 4 (1) - (3) F F 3 F 2. F F F F F F F F F 3. F F F F F F F F F F F F F F F F F FF